Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase NA 1Phase 3 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Lymphoid 10Other hematologic neoplasm 8Head & Neck 8Thoracic 4Sarcoma 4CNS 4Myeloid 2Genitourinary 2Classical hematology 2Tumor-Agnostic 1Plasma cell 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Pituitary Neoplasms 1

Interventions

lutetium Lu 177 dotatate 2Fluorouracil 2Everolimus 2trametinib 1toripalimab 1fosbretabulin 1fluorocholine 1dabrafenib 1combretastatin 1cobimetinib 1anlotinib 1Water 1Vemurafenib 1Testosterone 1Temozolomide 1Somatostatin 1Sodium Iodide 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Radiofrequency Ablation 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1PE regimen 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Injections 1Erythromycin 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Radiotherapy × Endocrine × Clear all
NCT04244708 2020-01-28

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Peking Union Medical College Hospital

Phase 2/3 Unknown
150 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡